VR Adviser as of Sept. 30, 2021
Portfolio Holdings for VR Adviser
VR Adviser holds 26 positions in its portfolio as reported in the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Instil Bio | 15.8 | $123M | 6.9M | 17.88 | |
| Aclaris Therapeutics (ACRS) | 10.6 | $82M | 4.6M | 18.00 | |
| Celldex Therapeutics (CLDX) | 7.6 | $59M | 1.1M | 53.99 | |
| Aadi Bioscience (AADI) | 5.8 | $45M | 1.5M | 29.37 | |
| Vistagen Therapeutics | 5.6 | $44M | 16M | 2.74 | |
| Altimmune (ALT) | 5.5 | $43M | 3.8M | 11.31 | |
| Olema Pharmaceuticals (OLMA) | 5.4 | $42M | 1.5M | 27.56 | |
| Travere Therapeutics (TVTX) | 5.4 | $42M | 1.7M | 24.25 | |
| Relmada Therapeutics (RLMD) | 4.7 | $36M | 1.4M | 26.21 | |
| Gh Research Ord Sh (GHRS) | 4.7 | $36M | 1.6M | 22.06 | |
| Kinnate Biopharma (KNTE) | 4.4 | $34M | 1.5M | 23.02 | |
| Marinus Pharmaceuticals (MRNS) | 3.9 | $30M | 2.6M | 11.38 | |
| Graphite Bio | 3.4 | $26M | 1.6M | 16.39 | |
| Centessa Pharmaceuticals Spons Adr (CNTA) | 2.4 | $19M | 1.1M | 16.70 | |
| Nuvalent Inc-a (NUVL) | 2.3 | $18M | 804k | 22.55 | |
| Corvus Pharmaceuticals (CRVS) | 2.1 | $17M | 3.4M | 4.84 | |
| Cullinan Oncology (CGEM) | 2.0 | $16M | 706k | 22.57 | |
| Atyr Pharma (LIFE) | 1.8 | $14M | 1.6M | 9.08 | |
| Athira Pharma (ATHA) | 1.4 | $11M | 1.2M | 9.38 | |
| Pharvaris N V (PHVS) | 1.3 | $9.8M | 553k | 17.73 | |
| Cogent Biosciences (COGT) | 1.2 | $9.2M | 1.1M | 8.41 | |
| CVRX (CVRX) | 1.1 | $8.8M | 533k | 16.54 | |
| Akoya Biosciences (AKYA) | 0.7 | $5.6M | 400k | 13.96 | |
| Astria Therapeutics (ATXS) | 0.6 | $4.8M | 539k | 8.84 | |
| Tricida | 0.2 | $1.8M | 391k | 4.64 | |
| Miragen Therapeutics (VRDN) | 0.0 | $321k | 20k | 16.47 |
